Osimertinib - NDSRI's
References
FAQ's
References
- Rood, Johannes J. M. ; van Bussel, Mark T. J.; Schellens, Jan H. M.; Beijnen, Jos H.; Sparidans, Rolf W.,” Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma”, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 1031, Pages: 80-85, 2016
- Rood, J. J. M.; van Haren, M. J.; Beijnen, J. H.; Sparidans, R. W., “Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry”, Journal of Pharmaceutical and Biomedical Analysis, Volume: 177, Pages: 112871, 2020
- Butterworth, Sam; Finlay, Maurice Raymond Verschoyle; Ward, Richard Andrew; Kadambar, Vasantha Krishna; Chandrashekar, Reddy C.; Murugan, Andiappan; Redfearn, Heather Marie, “2-(2,4,5-substituted-anilino) pyrimidine compounds”, AstraZeneca AB, Sweden, US8946235B2, Feb 3, 2015
Frequently Asked Questions
What are the most common Osimertinib impurities?
The most common impurities in Osimertinib are N-desmethyl Osimertinib, Osimertinib N-oxide, Osimertinib oxide, and Osimertinib desmethoxy.
What impact do Osimertinib impurities have on the stability of the drug?
Impurities in Osimertinib can potentially affect its stability, leading to drug degradation over time. It could affect the safety, efficacy, and shelf life of the drug.
How are Osimertinib impurities detected?
Impurities in Osimertinib detection are through analytical methods such as high-performance liquid chromatography (HPLC), liquid chromatography mass spectrometry (LC-MS), etc.
How are Osimertinib impurities removed?
Osimertinib impurities removal is by purification steps, such as crystallization or chromatography.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.